This inventor holds 3 USPTO granted patents. Top assignee: Abbott Laboratories Corporation. Active years: 1997-1998.
Company Filing History:
Years Active: 1997-1998
Title: Mark F Knigge: Innovator in Hepatitis Research
Introduction
Mark F Knigge is a notable inventor based in Grayslake, IL (US). He has made significant contributions to the field of medical research, particularly in the area of hepatitis viruses. With a total of 3 patents to his name, Knigge's work has had a profound impact on diagnostic and therapeutic applications.
Latest Patents
Knigge's latest patents include innovative developments in synthetic peptides related to Hepatitis GB Virus (HGBV). These synthetic peptides are useful for a variety of diagnostic and therapeutic applications. His patents also encompass kits for utilizing HGBV nucleic acid or amino acid sequences, as well as antibodies that specifically bind to HGBV. Additionally, he has developed methods for producing both polyclonal and monoclonal antibodies from HGBV peptides. Another significant patent involves monoclonal antibodies that specifically bind to the Hepatitis E Virus (HEV), particularly targeting the HEV orf-2 antigen. This patent also includes hybridoma cell lines that secrete these monoclonal antibodies, along with methods for their use and assay kits containing these antibodies.
Career Highlights
Mark F Knigge is currently associated with Abbott Laboratories Corporation, a leading company in the healthcare sector. His work at Abbott has allowed him to focus on groundbreaking research that addresses critical health issues related to hepatitis viruses.
Collaborations
Throughout his career, Knigge has collaborated with esteemed colleagues, including Deborah A Paul and Dominique P Bridon. These collaborations have further enhanced the quality and impact of his research.
Conclusion
Mark F Knigge's contributions to hepatitis research through his patents and work at Abbott Laboratories Corporation highlight his role as an influential inventor in the medical field. His innovative approaches continue to pave the way for advancements in diagnostic and therapeutic solutions.